U.S., April 2 -- ClinicalTrials.gov registry received information related to the study (NCT06905795) titled 'Screening and Intervention of MASLD in Children' on Feb. 27.
Brief Summary: Non-alcoholic fatty liver disease (NAFLD) in children and adolescents has recently been renamed metabolic dysfunction-associated steatotic liver disease (MASLD). It has become one of the leading chronic liver diseases in children. The prevalence of MASLD is 6.3% among the general pediatric population and 40.4% among overweight and obese children, with an increasing trend each year. MASLD increases the risk of various metabolic diseases and can eventually lead to liver fibrosis or hepatocellular carcinoma, contributing to the disease burden.
Previous work by...